<SEC-DOCUMENT>0001193125-25-059327.txt : 20250320
<SEC-HEADER>0001193125-25-059327.hdr.sgml : 20250320
<ACCEPTANCE-DATETIME>20250320164817
ACCESSION NUMBER:		0001193125-25-059327
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20250319
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250320
DATE AS OF CHANGE:		20250320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akebia Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001517022
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				208756903
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36352
		FILM NUMBER:		25757152

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-871-2098

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d908870d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:akba="http://akebia.com/20250319" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2025-03-19_to_2025-03-19">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-313">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-03-19_to_2025-03-19">0001517022</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="akba-20250319.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-03-19_to_2025-03-19"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-03-19</xbrli:startDate> <xbrli:endDate>2025-03-19</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-324">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 OR 15(D)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-03-19_to_2025-03-19" format="ixt:datemonthdayyearen" id="ixv-325">March 19, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-326">AKEBIA THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-03-19_to_2025-03-19" format="ixt-sec:stateprovnameen" id="ixv-327">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-328">001-36352</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-329">20-8756903</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-330">245 First Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-331">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-03-19_to_2025-03-19" format="ixt-sec:stateprovnameen" id="ixv-332">Massachusetts</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-333">02142</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-334">(617)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-335">871-2098</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-03-19_to_2025-03-19" format="ixt-sec:boolballotbox" id="ixv-336">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-03-19_to_2025-03-19" format="ixt-sec:boolballotbox" id="ixv-337">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-03-19_to_2025-03-19" format="ixt-sec:boolballotbox" id="ixv-338">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-03-19_to_2025-03-19" format="ixt-sec:boolballotbox" id="ixv-339">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-340">Common Stock, par value $0.00001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-341">AKBA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Capital Market</span> </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-03-19_to_2025-03-19" format="ixt-sec:boolballotbox" id="ixv-342">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;19, 2025, Akebia Therapeutics, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Leerink Partners LLC and Piper Sandler&#160;&amp; Co., as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), relating to an underwritten public offering (the &#8220;Offering&#8221;) of 25,000,000 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.00001 per share (the &#8220;Common Stock&#8221;). All Shares are being sold by the Company. The public offering price is $2.00 per share, and the Underwriters have agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $1.88 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters a <span style="white-space:nowrap">30-day</span> option to purchase up to 3,750,000 additional shares of Common Stock (the &#8220;Additional Shares&#8221;) at the public offering price per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates that the net proceeds from the Offering will be approximately $46.5&#160;million, or approximately $53.6&#160;million if the Underwriters exercise in full their option to purchase the Additional Shares, in each case, after deducting underwriting discounts and commissions and estimated offering expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares and any Additional Shares will be issued pursuant to a shelf registration statement on Form <span style="white-space:nowrap">S-3</span> that was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) (File <span style="white-space:nowrap">No.&#160;333-281903)</span> on September&#160;3, 2024 and declared effective by the SEC on September&#160;12, 2024. A prospectus supplement relating to the Offering has been filed with the SEC. The closing of the Offering is expected to take place on March&#160;21, 2025, subject to the satisfaction of customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the legal opinion and consent of Wilmer Cutler Pickering Hale and Dorr LLP relating to the Shares and the Additional Shares is attached as Exhibit 5.1 hereto. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;7.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that it is financed to achieve profitability based on its current operating plan. The Company has based this estimate on assumptions that may prove to be wrong, and the Company may never achieve profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Current Report on Form <span style="white-space:nowrap">8-K</span> shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;19, 2025, the Company issued a press release (the &#8220;Press Release&#8221;) announcing the pricing of the Offering. A copy of the Press Release has been filed as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Note Regarding Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements of the Company that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;build,&#8221; &#8220;can,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;designed,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;future,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;strategy,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements relating to the anticipated closing of the Offering and the Company&#8217;s ability to achieve profitability. Actual results may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to market conditions that may affect the timing, terms and conditions of the Offering and the satisfaction of customary closing conditions related to the Offering. There can be no assurance that the Company will be able to complete the Offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements. Additional risks and uncertainties relating to the Offering, the Company and its business can be found under the caption &#8220;Risk Factors&#8221; included in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2024, the Company&#8217;s prospectus supplement filed with the SEC on March&#160;20, 2025 and other filings that the Company may make with the SEC in the future. Any forward-looking statements contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> (except as otherwise noted) speak only as of the date hereof, and, except as required by law, the Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:7%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d908870dex11.htm">Underwriting Agreement, dated March&#160;19, 2025, by and among the Company, Leerink Partners LLC and Piper Sandler&#160;&amp; Co. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d908870dex51.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d908870dex51.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d908870dex991.htm">Press Release issued by the Company on March&#160;19, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">AKEBIA THERAPEUTICS, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: March&#160;20, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John P. Butler</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name: John P. Butler</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title: President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d908870dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>25,000,000 Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AKEBIA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK, PAR VALUE $0.00001 PER SHARE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;19,
2025 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">March&nbsp;19, 2025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Representatives named in Schedule I hereto </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">for the Underwriters named in Schedule II hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Akebia Therapeutics,
Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several underwriters named in Schedule II hereto (the &#147;<B>Underwriters</B>&#148;), for whom you are acting as representatives (the
&#147;<B>Representatives</B>&#148;), the number of shares of its common stock, par value $0.00001 per share, set forth in Schedule I hereto (the &#147;<B>Firm Shares</B>&#148;). The Company also proposes to issue and sell to the several Underwriters
not more than the number of additional shares of its common stock, par value $0.00001 per share, set forth in Schedule I hereto (the &#147;<B>Additional Shares</B>&#148;) if and to the extent that you, as Representatives, shall have determined to
exercise, on behalf of the Underwriters, the right to purchase such shares of common stock granted to the Underwriters in Section&nbsp;2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the
&#147;<B>Shares</B>.&#148; The shares of common stock, par value $0.00001 per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the &#147;<B>Common Stock</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a registration statement, including a
prospectus, on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the file number of which is set forth in Schedule I hereto), relating to the securities (the &#147;<B>Shelf Securities</B>&#148;), including the Shares, to be issued from time to time
by the Company. The registration statement as amended to the date of this Agreement, including the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule&nbsp;430A or Rule 430B under the
Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), is hereinafter referred to as the &#147;<B>Registration Statement</B>&#148; and the related prospectus included in the Registration Statement at the time of its
effectiveness covering the Shelf Securities in the form first used to confirm sales of the Shares (or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act)
is hereinafter referred to as the &#147;<B>Base Prospectus.</B>&#148; If the Company has filed an abbreviated registration statement to register additional shares of Common Stock pursuant to Rule 462(b) under the Securities Act (the &#147;<B>Rule
462 Registration Statement</B>&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration Statement. The Base Prospectus, as supplemented by the prospectus supplement
specifically relating to the Shares in the form first used to confirm sales of the Shares (or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act) is
hereinafter referred to as the &#147;<B>Prospectus</B>,&#148; and the term &#147;<B>preliminary prospectus</B>&#148; means any preliminary form of the Prospectus. For purposes of this Agreement, &#147;<B>free </B>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>writing prospectus</B>&#148; has the meaning set forth in Rule 405 under the Securities Act, &#147;<B>Time of Sale Prospectus</B>&#148; means the documents and pricing information set forth
opposite the caption &#147;Time of Sale Prospectus&#148; in Schedule I hereto, and &#147;<B>broadly available road show</B>&#148; means a &#147;bona fide electronic road show&#148; as defined in Rule 433(h)(5) under the Securities Act that has been
made available without restriction by means of graphic communication to any person. As used herein, the terms &#147;Registration Statement,&#148; &#147;Base Prospectus,&#148; &#147;preliminary prospectus,&#148; &#147;Time of Sale Prospectus&#148;
and &#147;Prospectus&#148; shall include the documents, if any, incorporated by reference therein as of the date hereof. The terms &#147;<B>supplement</B>,&#148; &#147;<B>amendment</B>&#148; and &#147;<B>amend</B>&#148; as used herein with respect
to the Registration Statement, the Base Prospectus, the Time of Sale Prospectus, any preliminary prospectus or the Prospectus shall include all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange Act
of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), that are deemed to be incorporated by reference therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>Representations
and Warranties</I>. The Company represents and warrants to and agrees with each of the Underwriters that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The
Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose or pursuant to Section&nbsp;8A of the Securities Act are pending before or, to
the knowledge of the Company, threatened by the Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i) Each document, if any, filed or to be filed pursuant
to the Exchange Act and incorporated by reference in the Time of Sale Prospectus or the Prospectus complied or will comply when so filed in all material respects with the Exchange Act and the applicable rules and regulations of the Commission
thereunder, (ii)&nbsp;each part of the Registration Statement, when such part became effective, did not contain, and each such part, as amended or supplemented, if applicable, will not contain, any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading, (iii)&nbsp;the Registration Statement as of the date hereof does not contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein not misleading, (iv)&nbsp;the Registration Statement and the Prospectus comply, and as amended or supplemented, if applicable, will comply, in all material
respects with the Securities Act and the applicable rules and regulations of the Commission thereunder, (v)&nbsp;the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with the offering when the Prospectus is
not yet available to prospective purchasers and at the Closing Date (as defined in Section&nbsp;4), the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, (vi)&nbsp;each broadly available road show, if any, when considered together with the Time of
Sale Prospectus, does not contain any untrue statement of a material fact or omit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and (vii)&nbsp;the Prospectus does not contain and,
as amended or supplemented, if applicable, will not contain, any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company is not an &#147;ineligible issuer&#148; in connection with the offering pursuant to Rules 164, 405 and 433
under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act and
the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of, or used or
referred to by, the Company complies or will comply in all material respects with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Except for the free writing prospectuses, if any,
identified in Schedule I hereto forming part of the Time of Sale Prospectus, and electronic road shows, if any, each furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior consent,
prepare, use or refer to, any free writing prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company has been duly incorporated, is validly existing as
a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own or lease its property and to conduct its business as described in the Time of Sale Prospectus and is duly qualified
to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good
standing would not have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each
subsidiary of the Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its
business as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification,
except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the Company and its subsidiaries, taken as a whole; all of the issued shares of capital stock of each subsidiary of the
Company have been duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are owned directly by the Company, free and clear of all liens, encumbrances, equities or claims, except such as
are described in the Time of Sale Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) This Agreement has been duly authorized, executed and delivered by the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The authorized capital stock of the Company conforms in all material respects as to legal matters to the
description thereof contained in each of the Time of Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The shares of Common Stock
outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this
Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and the issuance of such Shares will not be subject to any preemptive or similar rights that have not been waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement
will not contravene (i)&nbsp;any provision of applicable law, (ii)&nbsp;the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> of the Company, (iii)&nbsp;any agreement or other instrument binding upon the Company or any
of its subsidiaries, or (iv)&nbsp;any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, except, in the case of each of clauses (i), (iii) and (iv), as would not have a
material adverse effect on the Company and its subsidiaries, taken as a whole, or on the performance by the Company of its obligations under this Agreement; and no consent, approval, authorization or order of, or qualification with, any governmental
body or agency is required for the performance by the Company of its obligations under this Agreement, except such as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) There has not occurred any material adverse change, or any development that would reasonably be expected to result in a
prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business, management or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) There are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened, to which the
Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i)&nbsp;other than proceedings accurately described in all material respects in the Time of Sale Prospectus and
proceedings that would not reasonably be expected to have a material adverse effect on the Company and its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
subsidiaries, taken as a whole, or on the power or ability of the Company to perform its obligations under this Agreement or (ii)&nbsp;that are required to be described in the Registration
Statement or the Prospectus and are not so described; and there are no statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the
Registration Statement that are not described or filed as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Each preliminary prospectus filed pursuant to
Rule&nbsp;424 under the Securities Act complied when so filed in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) The Company is not, and after giving effect to the offering and sale of the Shares and the application of the proceeds
thereof as described in the Time of Sale Prospectus and the Prospectus will not be, required to register as an &#147;investment company&#148; as such term is defined in the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company and its subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign, federal, state and local
laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<B>Environmental Laws</B>&#148;), (ii) have received all permits, licenses or
other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with
Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, reasonably be expected to have a
material adverse effect on the Company and its subsidiaries, taken as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) There are no costs or liabilities
associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for <FONT STYLE="white-space:nowrap">clean-up,</FONT> closure of properties or compliance with Environmental Laws or any permit,
license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its
subsidiaries, taken as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) There are no contracts, agreements or understandings between the Company and any
person granting such person the right to require the Company to file a registration statement under the Securities Act with respect to any securities of the Company in connection with the offering of the Shares or to require the Company to include
such securities with the Shares registered pursuant to the Registration Statement that have not been waived. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) Neither the Company nor any of its subsidiaries, nor any director or
officer of the Company or any of its subsidiaries, nor, to the Company&#146;s knowledge, any agent, affiliate, employee or representative of the Company or of any of its subsidiaries, has taken or will take any action in furtherance of an offer,
payment, promise to pay, or authorization or approval of the payment or giving of money, property, gifts or anything else of value, directly or indirectly, to any &#147;government official&#148; (including any officer or employee of a government or
government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) to
influence official action or secure an improper advantage or has violated any applicable anti-corruption laws; and the Company and its subsidiaries have conducted their businesses in compliance with applicable anti-corruption laws and have
instituted and maintain policies and procedures designed to promote and achieve compliance with such laws and with the representation and warranty contained herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) The operations of the Company and its subsidiaries are and have been conducted at all times in material compliance with all
applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act
of 2001 (USA PATRIOT Act), the Money Laundering Control Act of 1986, the Anti-Money Laundering Act of 2020 and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business, the rules and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Anti-Money Laundering Laws</B>&#148;), and no action, suit or proceeding by
or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) (i) None of the Company, any of its subsidiaries, or, to the Company&#146;s knowledge, any director, officer, employee,
agent, affiliate, or representative of the Company or any of its subsidiaries, is an individual or entity (&#147;<B>Person</B>&#148;) that is, or is owned or controlled by one or more Persons that are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#146;s Office of Foreign Assets
Control (&#147;<B>OFAC</B>&#148;), the United Nations Security Council (&#147;<B>UNSC</B>&#148;), the European Union (&#147;<B>EU</B>&#148;), His Majesty&#146;s Treasury (&#147;<B>HMT</B>&#148;), or other relevant sanctions authority (collectively,
&#147;<B>Sanctions</B>&#148;), or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) located, organized or resident in a country or territory that is the subject of
Sanctions (including, without limitation, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, or any other Covered Region of
Ukraine identified pursuant to Executive Order 14065, Crimea, Cuba, Iran, North Korea and Syria). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company will not, directly or indirectly, use the proceeds of the offering, or
lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)
to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) to fund or facilitate any money laundering or terrorist financing activities; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) in any other manner that will result in a violation of any Anti-Corruption Laws, Anti-Money Laundering Laws or Sanctions by
any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Company
and its subsidiaries have not in the past five years knowingly engaged in, are not now knowingly engaged in, and will not knowingly engage in, any dealings or transactions with any Person, or in any country or territory that, at the time of the
dealing or transaction is or was the subject of Sanctions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) Subsequent to the respective dates as of which information
is given in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, (i)&nbsp;the Company and its subsidiaries have not incurred any material liability or obligation, direct or contingent, nor entered into any material
transaction; (ii)&nbsp;the Company and its subsidiaries have not purchased any of its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than ordinary and customary
dividends; and (iii)&nbsp;there has not been any material change in the capital stock, <FONT STYLE="white-space:nowrap">short-term</FONT> debt or <FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company or its subsidiaries, except in
each case as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The Company and its subsidiaries do not own any real property. The Company and its subsidiaries have good and marketable
title to all personal property owned by them that is material to the business of the Company, in each case free and clear of all liens, encumbrances and defects, except such as are described in the Time of Sale Prospectus or such as do not
materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or its subsidiaries; and any real property and buildings held under lease by the Company or its subsidiaries
are held by each under valid, subsisting and enforceable leases with such exceptions as would not reasonably be expected to have a material adverse effect on the Company, except as described in the Time of Sale Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) The Company and its subsidiaries own or are licensed rights to, or
otherwise have rights to exploit, all Intellectual Property (as defined below) necessary for the conduct of the Company&#146;s business as now currently conducted or as currently proposed to be conducted by it as disclosed in the Time of Sale
Prospectus, except as disclosed in the Time of Sale Prospectus or except as would not reasonably be expected to have a material adverse effect on the Company. To the knowledge of the Company, there is no infringement, misappropriation or violation,
or the occurrence of any event that with notice or the passage of time would constitute any of the foregoing, (i)&nbsp;by third parties of any Intellectual Property owned by or licensed to the Company or any of its subsidiaries or (ii)&nbsp;by the
Company or any of its subsidiaries of any Intellectual Property of any third parties, in each case, except as disclosed in the Time of Sale Prospectus or except as would not reasonably be expected to have a material adverse effect on the Company.
There is no pending, or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others to which the Company or any of its subsidiaries is a party or otherwise, challenging the Company&#146;s or any of its subsidiaries&#146;
rights in or to, or exploitation of, any such Intellectual Property, except as disclosed in the Time of Sale Prospectus. Such Intellectual Property owned by the Company and its subsidiaries and, to the knowledge of the Company, such Intellectual
Property licensed to the Company and its subsidiaries have not been adjudged invalid or unenforceable, in whole or in part, and there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others
challenging the validity, enforceability or scope of any such Intellectual Property, except as disclosed in the Time of Sale Prospectus. There is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others
that the Company or its subsidiaries infringe, misappropriate or otherwise violate any Intellectual Property or other proprietary rights of others. The Company and its subsidiaries have not received any written notice of such claim and the Company
has no knowledge of any other fact that would form a reasonable basis for any such claim. To the knowledge of the Company, the Company and its subsidiaries have complied with the terms of each agreement pursuant to which any Intellectual Property
has been licensed to the Company and its subsidiaries, and all such agreements are in full force and effect, except in each case as would not reasonably be expected to have a material adverse effect. None of the Intellectual Property used by the
Company or its subsidiaries in its business has been obtained or is being used by the Company or its subsidiaries in violation of any contractual obligation binding on the Company or its subsidiaries. To the knowledge of the Company, no employee or
independent contractor of the Company or its subsidiaries is in or has ever been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement,
<FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any restrictive covenant to or with a former employer or independent contractor where
the basis of such violation relates to such employee&#146;s employment or independent contractor&#146;s engagement with the Company or its subsidiaries or actions undertaken while employed or engaged with the Company or its subsidiaries, except as
disclosed in the Time of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Sale Prospectus. All founders, key employees and any other employees involved in the development of Intellectual Property on behalf of the Company have executed an invention assignment agreement
whereby such founders and employees presently assign all of their right, title and interest in and to such Intellectual Property to the Company, and, to the knowledge of the Company, no such agreement has been breached or violated. The Company uses,
and has used, commercially reasonable efforts to appropriately maintain the confidentiality of all information intended to be maintained as confidential. &#147;<B>Intellectual Property</B>&#148; shall mean all patents, patent applications, trade and
service marks, trade names, copyrights, licenses, inventions, trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> domain names and all similar intellectual property and rights, including registrations and applications for registration
thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) No material labor dispute with the employees of the Company and its subsidiaries exists, except as described
in the Time of Sale Prospectus, or, to the knowledge of the Company, is imminent; and the Company and its subsidiaries are not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers,
manufacturers or contractors that would reasonably be expected to have a material adverse effect on the Company or its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) The Company and its subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as management of the Company reasonably believes are prudent and customary in the businesses in which they are engaged; neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or
applied for; and the Company and its subsidiaries have no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage is scheduled to expire or to obtain similar coverage from similar insurers as may
be necessary to continue its business at a cost that would not have a material adverse effect on the Company, except as described in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) Since January&nbsp;1, 2022, neither the Company nor any of its subsidiaries have received any FDA Form 483, notice of
adverse finding, warning letter, untitled letter or other correspondence or notice from the U.S. Food and Drug Administration (&#147;<B>FDA</B>&#148;) or any similar regulatory authority alleging or asserting material noncompliance by the Company or
its subsidiaries. There have been no recalls, market withdrawals, safety alerts, &#147;dear healthcare provider&#148; letters, or other notices or actions relating to an alleged lack of safety, efficacy, or regulatory compliance of any Company
product and, to the Company&#146;s knowledge, there are no facts that would be reasonably likely to result in such notice or action. The Company and its subsidiaries are not parties to nor have any ongoing reporting obligations pursuant to any
corporate integrity agreement, deferred or <FONT STYLE="white-space:nowrap">non-prosecution</FONT> agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental authority. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) The Company and its subsidiaries, and to the Company&#146;s knowledge,
its respective directors, officers, employees, agents, affiliates and representatives, are, and at all times have been, in compliance in all material respects with all health care laws applicable to the Company or its subsidiaries, respectively, or
any of their respective products or activities, including, but not limited to, the federal Anti-Kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the Civil Monetary Penalties Law (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7a(a)(5)),</FONT> the civil False Claims Act (31 U.S.C. &#167;&#167;3729 et seq.), the administrative False Claims Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> all criminal laws
relating to health care fraud and abuse, including but not limited to 18 U.S.C. &#167;&#167; 286, 287, 1035, 1347, 1349 and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C.
&#167; 1320d et seq.) (&#147;HIPAA&#148;), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.), the exclusion laws (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7),</FONT> Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), any other law governing or pertaining to a government healthcare program, including the collection
and reporting requirements, and the processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations relating to the Medicaid Drug Rebate Program (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1396r-8)</FONT>
and any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1395w-3a),</FONT> the Public Health Service Act (42 U.S.C. &#167; 256b), the VA Federal Supply Schedule (38 U.S.C.
&#167; 8126) or under any state pharmaceutical assistance program or U.S. Department of Veterans Affairs agreement, and any successor government programs, the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et seq.), the Public Health
Service Act (42 U.S.C. &#167; 201 et seq.), the Physician Payments Sunshine Act (42 USC &#167; <FONT STYLE="white-space:nowrap">1320a-7h),</FONT> any similar local, state or federal laws and the regulations promulgated pursuant to such laws
(collectively, the &#147;<B>Health Care Laws</B>&#148;), and have not engaged in activities which are, as applicable, prohibited or cause for civil penalties or mandatory or permissive exclusion from Medicare, Medicaid or any other state health care
program or federal health care program. The Company and its subsidiaries have not received any notification, correspondence or any other written or oral communication, including, without limitation, notification of any pending or threatened claim,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action, from any governmental authority of potential or actual <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or liability of, the Company or its subsidiaries
under any Health Care Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) The Company and its subsidiaries possess, and are in compliance in all material respects
with the terms of, all certificates, approvals, clearances, registrations, exemptions, franchises, licenses, permits and other authorizations necessary to conduct their respective businesses (collectively, &#147;<B>Licenses</B>&#148;), including,
without limitation, all Licenses required by the FDA and/or by any other U.S., state, local or foreign government or drug regulatory agency (collectively, the &#147;<B>Regulatory Agencies</B>&#148;). All Licenses are in full force and effect and the
Company and its subsidiaries are not in violation of any term of any License in any material respect. The Company and its subsidiaries have fulfilled </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and performed all of their obligations in all material respects with respect to the Licenses and, to the Company&#146;s knowledge, no event has occurred which allows, or after notice or lapse of
time would allow, revocation or termination thereof or results in any other material impairment of the rights of the holder of any License. Neither the Company nor any of its subsidiaries have received any notice of proceedings relating to the
revocation or modification of any Licenses that, if determined adversely to the Company or its subsidiaries, would reasonably be expected to have a material impact on the Company. To the Company&#146;s knowledge, no Regulatory Agency has taken any
action to limit, suspend or revoke any License possessed by the Company or its subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) The preclinical tests
and clinical trials that are described in, or the results of which are referred to in, the Time of Sale Prospectus were and, if still pending, are, being conducted in all material respects in accordance with the protocols established for each such
preclinical test or clinical trial and all Health Care Laws, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58 and 312, and, where applicable, the EU Clinical Trials Directive (Directive 2001/20/EC) as implemented; each description of
such tests and trials, and the results thereof, contained in the Time of Sale Prospectus is accurate and complete in all material respects and fairly presents the data about and derived from such tests and trials, and neither the Company nor any of
its subsidiaries have knowledge of any other studies or tests the results of which call into question in any material respect, the results described or referred to in the Time of Sale Prospectus; and neither the Company nor any of its subsidiaries
have received any notices or other correspondence from the FDA or any similar regulatory authority requiring the termination, suspension or material modification of any preclinical tests or clinical trials that are, or whose results of which are,
described or referred to in the Time of Sale Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) Neither the Company nor, to the Company&#146;s knowledge,
any of its subsidiaries, directors, officers, employees or agents, is debarred, suspended or excluded, or has been convicted of any crime or engaged in any conduct that could result in a debarment, suspension or exclusion, from any federal or state
government health care program under 21 U.S.C. &#167; 335a or any other Health Care Law. No claims, actions, proceedings or investigations that would reasonably be expected to result in such a debarment, suspension or exclusion are pending or, to
the Company&#146;s knowledge, threatened against the Company, or the subsidiaries, directors, officers, employees or agents of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) Except as described in the Time of Sale Prospectus, the Company and each of its subsidiaries maintain a system of internal
accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of
financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization;
(iv)&nbsp;the recorded accountability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the
Commission&#146;s rules and guidelines applicable thereto. Except as described in the Time of Sale Prospectus, since the end of the Company&#146;s most recent audited fiscal year, there has been (i)&nbsp;no material weakness in the Company&#146;s
internal control over financial reporting (whether or not remediated) identified by the Company and (ii)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to
materially affect, the Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) Except as described in the Time of
Sale Prospectus, neither the Company nor any of its subsidiaries have sold, issued or distributed any shares of Common Stock during the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date hereof, including any sales pursuant
to Rule&nbsp;144A under, or Regulation&nbsp;D or S of the Securities Act, other than shares issued pursuant to an effective registration statement, employee benefit plans, qualified stock option plans or other employee compensation plans or pursuant
to outstanding options, rights or warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) The Company and its subsidiaries have filed all U.S. federal, state,
local and foreign tax returns required to be filed through the date of this Agreement or have requested extensions thereof (except where the failure to file would not, individually or in the aggregate, reasonably be expected to have a material
adverse effect on the Company or its subsidiaries, taken as a whole) and have paid all taxes required to be paid thereon (except for cases in which the failure to pay would not, individually or in the aggregate, reasonably be expected to have a
material adverse effect on the Company or its subsidiaries, taken as a whole, or, except as currently being contested in good faith and for which adequate reserves required by generally accepted accounting principles in the United States have been
created in the financial statements of the Company and its subsidiaries), and no tax deficiency has been determined adversely to the Company or any of its subsidiaries that, individually or in the aggregate, has had (nor do the Company or any of its
subsidiaries have any notice or knowledge of any tax deficiency which would reasonably be expected to be determined adversely to the Company or its subsidiaries and which would reasonably be expected to, individually or in the aggregate, have) a
material adverse effect on the Company or its subsidiaries, taken as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) The interactive data in eXtensible
Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines
applicable thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company and its subsidiaries (i)&nbsp;have not alone engaged in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication other than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the
consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and
(ii)&nbsp;have not authorized anyone other than the Underwriters to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. Neither the Company nor any of its subsidiaries have
distributed any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than those listed on Schedule III hereto. &#147;<B><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</B>&#148; means any oral or written communication with potential investors undertaken in reliance on Rule 163B under the Securities Act. &#147;<B>Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</B>&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a
written communication within the meaning of Rule 405 under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) As of the time of each sale of the
Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers, none of (i)&nbsp;the Time of Sale Prospectus, (ii)&nbsp;any free writing prospectus, when considered together with the Time of Sale
Prospectus, and (iii)&nbsp;any individual Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, when considered together with the Time of Sale Prospectus, included, includes or will
include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included
or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly
in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified (subject to normal <FONT
STYLE="white-space:nowrap">year-end</FONT> audit adjustments for interim financial statements); such financial statements have been prepared in conformity with generally accepted accounting principles in the United States applied on a consistent
basis throughout the periods covered thereby, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; the other financial
information included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly the
information shown thereby; any disclosures included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus regarding <FONT STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures&#148;
(as such term is defined by the rules and regulations of Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act, to the extent applicable; and the <I>pro
forma</I> financial information and the related notes thereto included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
been prepared in accordance with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and the assumptions underlying such <I>pro forma</I> financial information
are reasonable and are set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)
Ernst&nbsp;&amp; Young LLP, who have certified certain financial statements of the Company and its subsidiaries is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and
regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) (&#147;<B>PCAOB</B>&#148;) and as required by the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) Except as described in the Time of Sale Prospectus, the Company and its subsidiaries maintain an effective system of
&#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information
required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including controls and
procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries have carried out
evaluations of the effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) There is and has been no material failure on the part of the Company or, to the knowledge of the Company, any of the
Company&#146;s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith, including Section&nbsp;402 related to
loans and Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) The Company and its subsidiaries&#146; information
technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases, taken as a whole (collectively, &#147;<B>IT Systems</B>&#148;), are adequate for, and operate and perform in all material
respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted. The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies,
procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive,
confidential or regulated data (&#147;<B>Personal Data</B>&#148;)) used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except as would not, individually or in
the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. The Company and its subsidiaries are presently in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and
contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification, except as would not,
individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <I>Agreements to Sell and Purchase. </I>The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis
of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company the respective numbers of Firm Shares set forth in Schedule&nbsp;II hereto
opposite its name at the purchase price set forth in Schedule I hereto (the &#147;<B>Purchase Price</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the
representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to sell to the Underwriters the Additional Shares, and the Underwriters shall have the right to purchase, severally and not
jointly, up to the number of Additional Shares set forth in Schedule I hereto at the Purchase Price, provided, however, that the amount paid by the Underwriters for any Additional Shares shall be reduced by an amount per share equal to any dividends
declared by the Company and payable on the Firm Shares but not payable on such Additional Shares. You may exercise this right on behalf of the Underwriters in whole or from time to time in part by giving written notice not later than 30 days after
the date of the Prospectus. Any exercise notice shall specify the number of Additional Shares to be purchased by the Underwriters and the date on which such shares are to be purchased. Each purchase date must be at least one business day after the
written notice is given and may not be earlier than the closing date for the Firm Shares nor later than ten business days after the date of such notice. On each day, if any, that Additional Shares are to be purchased (an &#147;<B>Option Closing
Date</B>&#148;), each Underwriter agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate fractional shares as you may determine) that bears the same proportion to the total number of
Additional Shares to be purchased on such Option Closing Date as the number of Firm Shares set forth in Schedule II hereto opposite the name of such Underwriter bears to the total number of Firm Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>Public Offering</I>. The Company is advised by you that the Underwriters propose to make a public offering of their respective portions
of the Shares as soon after the Registration Statement and this Agreement have become effective as in your judgment is advisable. The Company is further advised by you that the Shares are to be offered to the public upon the terms set forth in the
Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I>Payment and Delivery. </I>Payment for the Firm Shares shall be made to the Company in Federal or other funds immediately
available in New York City on the closing date and time set forth in Schedule I hereto, or at such other time on the same or such other date, not later than the fifth business day thereafter, as shall be mutually agreed in writing by you and the
Company. The time and date of such payment are hereinafter referred to as the &#147;<B>Closing Date</B>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for any Additional Shares shall be made to the Company in Federal or other funds
immediately available in New York City on the date specified in the corresponding notice described in Section&nbsp;2 or at such other time on the same or on such other date, in any event not later than the fifth business day thereafter, as may be
mutually agreed in writing by you and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Firm Shares and the Additional Shares shall be registered in such names and in
such denominations as you shall request in writing not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be, for the respective accounts of the several Underwriters, with any transfer
taxes payable in connection with the transfer of the Shares to the Underwriters duly paid, against payment of the Purchase Price therefor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>Conditions to the Underwriters</I><I>&#146;</I><I> Obligations</I>. The several obligations of the Underwriters are subject to the
following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The representations and warranties of the Company contained in this Agreement shall be true and
correct, in each case, on the date hereof and on and as of the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subsequent to the execution and delivery
of this Agreement and prior to the Closing Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) there shall not have occurred any downgrading, nor shall any notice have been given
of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any of the securities of the Company or any of its subsidiaries by any
&#147;nationally recognized statistical rating organization,&#148; as such term is defined in Section&nbsp;3(a)(62) of the Exchange Act; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) there shall not have occurred any change, or any development that would reasonably be expected to result in a prospective change, in the
condition, financial or otherwise, or in the earnings, business, management or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus that, in your judgment, is material and adverse and
that makes it, in your judgment, impracticable to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive
officer of the Company, to the effect set forth in Section&nbsp;5(a) and Section&nbsp;5(b)(i) above and to the effect that the Company has complied in all material respects with all of the agreements and satisfied all of the conditions on its part
to be performed or satisfied hereunder on or before the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officer signing and delivering such certificate may rely upon the best of his or her
knowledge as to proceedings threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Underwriters shall have received on the Closing Date an opinion and
negative assurance letter of Wilmer Cutler Pickering Hale and Dorr LLP, outside counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Underwriters shall have received on the Closing Date an opinion of Proskauer Rose LLP, intellectual property counsel
for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The
Underwriters shall have received on the Closing Date an opinion of Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriters, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinion of Wilmer Cutler Pickering Hale and Dorr LLP described in Section&nbsp;5(d) above and the opinion of Proskauer Rose LLP described
in Section&nbsp;5(e) above shall be rendered to the Underwriters at the request of the Company and shall so state therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Underwriters shall have received, on each of the date hereof and the Closing Date, a certificate dated the date hereof
or the Closing Date, as the case may be, in form and substance satisfactory to the Representatives, from the chief financial officer of the Company on behalf of the Company as to the accuracy of certain financial and other information incorporated
by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Underwriters shall
have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing Date, as the case may be, in form and substance satisfactory to the Representatives, from Ernst&nbsp;&amp; Young LLP, independent public
accountants for the Company, containing statements and information of the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to certain financial statements and financial information contained in
the Registration Statement, the Time of Sale Prospectus and the Prospectus; <I>provided</I> that such letter delivered on the Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off</FONT> date&#148; not earlier than the date hereof.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of Exhibit
A hereto, between you and certain officers and directors of the Company listed on Schedule IV hereto relating to sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to you on or before the date
hereof, shall be in full force and effect on the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) No order suspending the effectiveness of the Registration Statement
shall be in effect, and no proceeding for such purpose pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each free writing prospectus shall have been timely filed with
the Commission under the Securities Act (in the case of a free writing prospectus, to the extent required by Rule 433 under the Securities Act); and all requests by the Commission for additional information shall have been complied with to the
reasonable satisfaction of the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The several obligations of the Underwriters to purchase Additional
Shares hereunder are subject to the delivery to you on the applicable Option Closing Date of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The representations and
warranties of the Company contained in this Agreement shall be true and correct, in each case, on the date hereof and on and as of the Option Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a certificate, dated the Option Closing Date and signed by an executive officer of the Company, confirming that the certificate delivered
on the Closing Date pursuant to Section&nbsp;5(c) hereof remains true and correct as of such Option Closing Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) an opinion of
Wilmer Cutler Pickering Hale and Dorr LLP, outside counsel for the Company, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by
Section&nbsp;5(d) hereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) an opinion of Proskauer Rose LLP, intellectual property counsel for the Company, dated the Option Closing
Date, to the same effect as the opinion required by Section&nbsp;5(e) hereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) an opinion of Latham&nbsp;&amp; Watkins LLP, counsel for
the Underwriters, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(g) hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) a certificate from the chief financial officer of the Company on behalf of the Company, dated the Option Closing Date, substantially in
the same form and substance as the certificate required by Section&nbsp;5(h) hereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) a letter dated the Option Closing Date, in form
and substance satisfactory to the Representatives, from Ernst&nbsp;&amp; Young LLP, independent public accountants for the Company substantially in the same form and substance as the letter furnished to the Underwriters pursuant to Section&nbsp;5(i)
hereof; <I>provided</I> that such letter delivered on the Option Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off</FONT> date&#148; not earlier than three business days prior to such Option Closing Date; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) No order suspending the effectiveness of the Registration Statement shall be in
effect, and no proceeding for such purpose pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each free writing prospectus shall have been timely filed with the Commission
under the Securities Act (in the case of a free writing prospectus, to the extent required by Rule 433 under the Securities Act); and all requests by the Commission for additional information shall have been complied with to the reasonable
satisfaction of the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) such other documents as you may reasonably request with respect to the good standing of the
Company, the due authorization and issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the issuance of such Additional Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>Covenants of the Company</I>. The Company covenants with each Underwriter as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) To furnish to you, without charge, a signed copy of the Registration Statement (including exhibits thereto and documents
incorporated by reference therein) and to deliver to each of the Underwriters during the period mentioned in Section&nbsp;6(g) or 6(h) below, as many copies of the Time of Sale Prospectus, the Prospectus, any documents incorporated by reference
therein and any supplements and amendments thereto or to the Registration Statement as you may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
Before amending or supplementing the Registration Statement, or the Time of Sale Prospectus or the Prospectus, in each case prior to the 30th day after the date of the Prospectus, to furnish to you a copy of each such proposed amendment or
supplement and not to file any such proposed amendment or supplement to which you reasonably object, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed
pursuant to such rule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To furnish to you a copy of each proposed free writing prospectus to be prepared by or on
behalf of, used by, or referred to by the Company and not to use or refer to any proposed free writing prospectus to which you reasonably object. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Not to take any action that would result in an Underwriter or the Company being required to file with the Commission
pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have been required to file thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) To advise you promptly, and confirm such advice in writing, (i)&nbsp;when any amendment to the Registration Statement has
been filed or becomes effective; (ii)&nbsp;when any supplement to the Time of Sale Prospectus, the Prospectus or any free writing prospectus or any amendment to the Prospectus has been filed or distributed; (iii)&nbsp;of any request by the
Commission for any amendment to the Registration Statement or any amendment or supplement to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information; (iv)&nbsp;of the
issuance by the Commission or any other governmental authority or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Time of Sale
Prospectus or the Prospectus or the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (v)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period (as
defined below) as a result of which the Prospectus, any of the Time of Sale Prospectus or any free writing prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Time of Sale Prospectus, or any such free writing prospectus is delivered to a purchaser, not misleading; (vi)&nbsp;of the receipt by the
Company of any notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act; and (vii)&nbsp;of the receipt by the Company of any notice
with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose, in each case of clauses (i)-(vii), to the extent such actions relate to the
offering of the Shares; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any preliminary prospectus, any of
the Time of Sale Prospectus or the Prospectus or suspending any such qualification of the Shares and, if any such order is issued, will seek to obtain as soon as possible the withdrawal thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company will qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as you
shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Shares; provided that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer
in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it
is not otherwise so subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a
time when the Prospectus is not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in
the light of the circumstances, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement then on file, or if, in the
opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or
supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is delivered to a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the
Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) If, during such period of time after the first date of the public offering of the Shares as in the opinion of counsel for
the Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in connection with sales by an Underwriter or dealer (the &#147;<B>Prospectus Delivery
Period</B>&#148;), any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof
the notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law,
forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses you will furnish to the Company) to which Shares may have been sold by you on behalf of the
Underwriters and to any other dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu
thereof the notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as you
shall reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) To make generally available to the Company&#146;s security holders and to you as soon as
practicable an earning statement covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section&nbsp;11(a) of the Securities
Act and the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Whether or not the transactions contemplated in this
Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all expenses incident to the performance of the Company&#146;s obligations under this Agreement, including: (i)&nbsp;the fees, disbursements and expenses of the
Company&#146;s counsel and the Company&#146;s accountants in connection with the registration and delivery of the Shares under the Securities Act and all other fees or expenses incurred by the Company in connection with the preparation and filing of
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company
and amendments and supplements to any of the foregoing, including the filing fees payable to the Commission relating to the Shares (within the time required by Rule 456(b)(1), if applicable), all printing costs associated therewith, and the mailing
and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified, (ii)&nbsp;all costs and expenses related to the transfer and delivery of the Shares to the Underwriters, including any transfer or other taxes
payable thereon, (iii)&nbsp;the cost of printing or producing any Blue Sky memorandum in connection with the offer and sale of the Shares under state securities laws and all expenses in connection with the qualification of the Shares for offer and
sale under state securities laws as provided in Section&nbsp;6(i) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky
memorandum, (iv)&nbsp;all filing fees and the reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification of the offering of the Shares by the Financial Industry Regulatory Authority,
(v)&nbsp;all costs and expenses incident to listing the Shares on the Nasdaq Capital Market, (vi)&nbsp;the cost of printing certificates representing the Shares, (vii)&nbsp;the costs and charges of any transfer agent, registrar or depositary,
(viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the
preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval
of the Company, travel and lodging expenses of the representatives and officers of the Company and any such consultants, (ix)&nbsp;the document production charges and expenses associated with printing this Agreement and (x)&nbsp;all other costs and
expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section; provided that the amount payable by the Company for related reasonable fees and disbursements of counsel to
the Underwriters pursuant to the foregoing clauses (iii)&nbsp;and (iv) shall not exceed in the aggregate $25,000. It is understood, however, that except as provided in this Section, Section&nbsp;8 entitled &#147;Indemnity and Contribution&#148; and
the last paragraph of Section&nbsp;10 below, the Underwriters will pay all of their costs and expenses, including fees and disbursements of their counsel, stock transfer taxes payable on resale of any of the Shares by them and any advertising
expenses connected with any offers they may make. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) If the third anniversary of the initial effective date of the
Registration Statement occurs before all the Shares have been sold by the Underwriters, prior to the third anniversary to file a new shelf registration statement and to take any other action necessary to permit the public offering of the Shares to
continue without interruption; references herein to the Registration Statement shall include the new registration statement declared effective by the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) If requested by the Representatives, to prepare a final term sheet
relating to the offering of the Shares, containing only information that describes the final terms of the offering in a form consented to by the Representatives, and to file such final term sheet within the period required by Rule 433(d)(5)(ii)
under the Securities Act following the date the final terms have been established for the offering of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also
covenants with each Underwriter that, without the prior written consent of the Representatives, it will not, during the restricted period set forth in Schedule I hereto (the &#147;<B>Restricted Period</B>&#148;), (1)&nbsp;offer, pledge, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock,
whether any such transaction described in clause&nbsp;(1) or (2)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, or (3)&nbsp;file any registration statement with the Commission relating to the
offering of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing
sentence shall not apply to (a)&nbsp;the Shares to be sold hereunder, (b)&nbsp;the issuance by the Company of shares of Common Stock upon the exercise of an option or warrant, the vesting of restricted stock units or the conversion of a security
outstanding on the date hereof as described in the Time of Sale Prospectus, the grant of new options or other equity awards pursuant to Nasdaq Listing Rule 5635(c)(4) or under employee or <FONT STYLE="white-space:nowrap">non-employee</FONT> director
benefit or stock purchase plans existing as of the date hereof and disclosed in the Time of Sale Prospectus, and the filing of one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating thereto, (c)&nbsp;the
establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of Common Stock, <I>provided</I> that (i)&nbsp;such plan does not provide for the transfer of Common
Stock during the Restricted Period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such announcement or filing
shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period or (d)&nbsp;the offer or issuance of up to an aggregate of 10% of shares of Common Stock outstanding immediately
following the issuance and sale of the Shares in connection with collaboration, intellectual property license or acquisition agreements or arrangements; <I>provided further</I>, that in the cases of clause (d), that the recipients of such shares
agree to be bound by a <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement in the form of Exhibit A hereto and delivers such agreement to the Underwriters prior to such issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>Covenants of the Underwriters</I>. Each Underwriter severally covenants with the
Company not to take any action that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not be required to be filed by
the Company thereunder, but for the action of the Underwriter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Indemnity and Contribution.</I> (a)&nbsp;The Company agrees to
indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act and each director, officer and affiliate of any
Underwriter within the meaning of Rule&nbsp;405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with
defending or investigating any such action or claim) arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus, the
Time of Sale Prospectus or any amendment or supplement thereto, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule
433(d) under the Securities Act, any road show as defined in Rule 433(h) under the Securities Act (a &#147;<B>road show</B>&#148;), or the Prospectus or any amendment or supplement thereto, or any Written Testing the Waters Communication arising out
of or based upon any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities arise out of,
or are based upon, any such untrue statement or omission or alleged untrue statement or omission based upon information furnished in writing to the Company by such Underwriter through you or by you expressly for use therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its affiliates, its
directors, its officers who sign the Registration Statement and each person, if any, who controls the Company within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the
foregoing indemnity from the Company to such Underwriter, but only with reference to information furnished in writing to the Company by such Underwriter through you or by you expressly for use in the Registration Statement, any preliminary
prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, road show, Written Testing the Waters Communication or the Prospectus or any amendment or supplement thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of
which indemnity may be sought pursuant to Section&nbsp;8(a) or 8(b), such person (the &#147;<B>indemnified party</B>&#148;) shall promptly notify the person against whom such indemnity may be sought (the &#147;<B>indemnifying party</B>&#148;) in
writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such
proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
such counsel shall be at the expense of such indemnified party unless (i)&nbsp;the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel,
(ii)&nbsp;the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or
potential differing interests between them, (iii)&nbsp;the indemnifying party has failed within a reasonable time to retain counsel reasonably satisfactory to the indemnified party, or (iv)&nbsp;the indemnified party shall have reasonably concluded
that there may be legal defenses available to it that are different from or in addition to those available to the indemnifying party. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party
in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties and that all such fees and
expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by the Representatives in the case of parties indemnified pursuant to Section&nbsp;8(a), and by the Company, in the case of parties indemnified pursuant to
Section&nbsp;8(b). The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party
agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to
reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its
written consent if (i)&nbsp;such settlement is entered into more than 90 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such settlement at least 30
days prior to such settlement being entered into, and (iii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the
prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified
party, unless such settlement (x)&nbsp;includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of
fault, culpability or a failure to act by or on behalf of any indemnified party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) To the extent the indemnification
provided for in Section&nbsp;8(a) or 8(b) is unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying
such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand from the offering of the Shares or (ii)&nbsp;if the allocation provided
by clause&nbsp;8(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;8(d)(i) above but also the relative fault of the Company on the one hand and
of the Underwriters on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company
on the one hand and the Underwriters on the other hand in connection with the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Shares (before deducting expenses) received by
the Company and the total underwriting discounts and commissions received by the Underwriters bear to the aggregate public offering price of the Shares set forth in the Prospectus. The relative fault of the Company on the one hand and the
Underwriters on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by
the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Underwriters&#146; respective obligations to contribute pursuant to this
Section&nbsp;8 are several in proportion to the respective number of Shares they have purchased hereunder, and not joint. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this
Section&nbsp;8 were determined by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in
Section&nbsp;8(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section&nbsp;8(d) shall be deemed to include, subject to the limitations set forth above, any legal or
other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section&nbsp;8, no Underwriter shall be required to contribute any amount in
excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of
such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The remedies provided for in this Section&nbsp;8 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The indemnity and contribution provisions contained in this
Section&nbsp;8 and the representations, warranties and other statements of the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i)&nbsp;any termination of this Agreement, (ii)&nbsp;any
investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any director, officer or affiliate of any Underwriter or by or on behalf of the Company, its officers or directors or any person controlling the Company
and (iii)&nbsp;acceptance of and payment for any of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <I>Termination</I>. The Underwriters may terminate this Agreement by
notice given by you to the Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on, or by, as the case may be, the New York Stock
Exchange or the Nasdaq Capital Market, (ii)&nbsp;trading of any securities of the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market,
(iii)&nbsp;a material disruption in securities settlement, payment or clearance services in the United States shall have occurred, (iv)&nbsp;any moratorium on commercial banking activities shall have been declared by Federal or New York State
authorities or (v)&nbsp;there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets or any calamity or crisis that, in your judgment, is material and adverse and which, singly or together with any other
event specified in this clause&nbsp;(v), makes it, in your judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus or the Prospectus.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <I>Effectiveness; Failure to Comply</I>. This Agreement shall become effective upon the execution and delivery hereof by the parties
hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, on the Closing Date or an Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse
to purchase Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase is not more than <FONT
STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of the Shares to be purchased on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set forth opposite their respective
names in Schedule&nbsp;II bears to the aggregate number of Firm Shares set forth opposite the names of all such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other proportions as you may specify, to purchase the
Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date; <I>provided</I> that in no event shall the number of Shares that any Underwriter has agreed to purchase pursuant to this Agreement be
increased pursuant to this Section&nbsp;10 by an amount in excess of <FONT STYLE="white-space:nowrap">one-ninth</FONT> of such number of Shares without the written consent of such Underwriter. If, on the Closing Date, any Underwriter or Underwriters
shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default occurs is more than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of Firm Shares to be purchased on
such date, and arrangements satisfactory to you and the Company for the purchase of such Firm Shares are not made within 72 hours after such default, this Agreement shall terminate without liability on the part of any
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company. In any such case either you or the Company shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order that the required
changes, if any, in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be effected. If, on an Option Closing Date, any Underwriter or Underwriters
shall fail or refuse to purchase Additional Shares and the aggregate number of Additional Shares with respect to which such default occurs is more than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of Additional Shares to
be purchased on such Option Closing Date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall have the option to (i)&nbsp;terminate their obligation hereunder to purchase the Additional Shares to be sold on such Option
Closing Date or (ii)&nbsp;purchase not less than the number of Additional Shares that such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters would have been obligated to purchase in the absence of such default. Any action taken
under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Agreement shall be terminated by the Underwriters because of any failure or refusal on the part of the Company to comply with the
terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement (which, for the purposes of this Section&nbsp;10, shall not include termination by the
Underwriters pursuant to clauses (i), (iii), (iv) or (v)&nbsp;of Section&nbsp;9), the Company will reimburse the Underwriters for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including
the fees and disbursements of their counsel) reasonably incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <I>Information Furnished by the Underwriters</I>. The statements set forth in the fifth paragraph concerning the public offering price and
the thirteenth paragraph concerning stabilization by the Underwriters, each appearing under the caption &#147;Underwriting&#148; in the Prospectus, constitute the only information furnished by or on behalf of the Underwriters, as such information is
referred to in Sections 1 and 8 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <I>Entire Agreement</I>. (a)&nbsp;This Agreement, together with any contemporaneous written
agreements and any prior written agreements (to the extent not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company and the Underwriters with respect to the preparation of any
preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the purchase and sale of the Shares. Additionally, the Underwriters are not advising the Company or any other person as to any legal, tax,
investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions
contemplated hereby, and the Underwriters shall not have any responsibility or liability to the Company with respect thereto. Any review by the Underwriters of the Company, the transactions contemplated hereby or other matters relating to such
transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company acknowledges that in connection with the offering of the
Shares: (i)&nbsp;the Underwriters have acted at arms&#146; length, are not agents of, and owe no fiduciary duties to, the Company or any other person, (ii)&nbsp;the Underwriters owe the Company only those duties and obligations set forth in this
Agreement and prior written agreements (to the extent not superseded by this Agreement), if any, and (iii)&nbsp;the Underwriters may have interests that differ from those of the Company. The Company waives to the full extent permitted by applicable
law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in connection with the offering of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <I>Recognition of the U.S. Special Resolution Regimes</I>. (a)&nbsp;In the event that any Underwriter that is a Covered Entity becomes
subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective
under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in
this Section&nbsp;13: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Covered Entity</B>&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167;
252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S. Special Resolution Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit
Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <I>Counterparts</I>. This Agreement may be signed in two or more counterparts, each of
which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile, electronic mail or other transmission
method as permitted by applicable law, and the parties hereto agree that any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. A party&#146;s electronic signature (complying
with the New York Electronic Signatures and Records Act (N.Y. State Tech. &#167;&#167; <FONT STYLE="white-space:nowrap">301-309),</FONT> as amended from time to time, or other applicable law) of this Agreement shall have the same validity and effect
as a signature affixed by the party&#146;s hand. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <I>Applicable Law</I>. This Agreement and any claim, controversy or dispute arising
under or related thereto shall be governed by and construed in accordance with the internal laws of the State of New York. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.
<I>Compliance with USA Patriot Act</I>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to
obtain, verify and record information that identifies their clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly
identify their clients. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <I>Submission to Jurisdiction</I>. The Company hereby submits to the exclusive jurisdiction of the U.S.
federal and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any objection which it may now
or hereafter have to the laying of venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and may be
enforced in any court to the jurisdiction of which Company is subject by a suit upon such judgment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <I>Persons Entitled to Benefit of
Agreement</I>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of the Underwriters
referred to in Section&nbsp;8 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No
purchaser of Shares from the Underwriters shall be deemed to be a successor merely by reason of such purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <I>Waiver of Jury
Trial</I>. Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <I>Headings</I>. The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be
deemed a part of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <I>Notices</I>. All communications hereunder shall be in writing and effective only upon
receipt and (a)&nbsp;if to the Underwriters shall be delivered, mailed or sent to you at the address set forth in Schedule I hereto; and (b)&nbsp;if to the Company shall be delivered, mailed or sent to the address set forth in Schedule I hereto.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B><B><I>The Remainder of This Page Intentionally Left Blank; Signature Page Follows</I></B><B>] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AKEBIA THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John P. Butler</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John P. Butler</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted as of the date hereof </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Leerink Partners LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">For itself and on behalf of the several Underwriters listed in Schedule II hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sean Pitt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sean Pitt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Senior Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Piper Sandler&nbsp;&amp; Co.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">For itself and on behalf of the several Underwriters listed in Schedule II hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chad Huber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Chad Huber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Representatives:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Co-Manager:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BTIG, LLC</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Registration Statement File No.:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">333-281903</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Time of Sale Prospectus</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1.&#8195;&#8201;Prospectus dated September&nbsp;12, 2024 relating to the Shelf Securities</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.&#8195;&#8201;The preliminary prospectus
supplement dated March&nbsp;19, 2025 relating to the Shares</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3.&#8195;&#8201;Firm Shares: 25,000,000</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Additional Shares: 3.750,000</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Price per share to the public: $2.00</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Lock-up</FONT> Restricted Period:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">60 days</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title of Shares to be purchased:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Common Stock of Akebia Therapeutics, Inc., par value $0.00001 per share</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Firm Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">25,000,000 shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Additional Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3,750,000 shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Purchase Price:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$1.88 a share</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Public Offering Price</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$2.00 a share</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Date and Time:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2025, 9:00 A.M. EDT</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address for Notices to Underwriters:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Avenue of the
Americas, 5th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10019</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Stuart R.
Nayman</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Nicollet Mall,
Suite 800</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis, Minnesota 55402</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax: (612) <FONT
STYLE="white-space:nowrap">313-3112</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Equity Capital Markets</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address for Notices to the Company:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">245 First Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts
02142</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE II </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Firm&nbsp;Shares&nbsp;To<BR>Be Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BTIG, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE III </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Written Testing the Waters Communications </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE IV </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Persons Delivering <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Directors: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adrian Adams </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Butler </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ron Frieson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steven Gilman, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Rogers </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cynthia Smith </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Myles Wolf, M.D. M.M.S.c. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LeAnne Zumwalt </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Officers: </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Butler </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steven Burke, M.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Erik Ostrowski </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nicholas Grund </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Malabre </P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IV-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> LETTER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#8195;], 2025 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Avenue of the Americas, 5th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">50 California St., Suite 3100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California 94111 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that Leerink Partners LLC (&#147;<B>Leerink Partners</B>&#148;) and Piper Sandler&nbsp;&amp; Co. (&#147;<B>Piper
Sandler</B>&#148; and together with Leerink Partners, the &#147;<B>Representatives</B>&#148;) propose to enter into an Underwriting Agreement (the &#147;<B>Underwriting Agreement</B>&#148;) with Akebia Therapeutics, Inc., a Delaware corporation
(together with any successor, the &#147;<B>Company</B>&#148;), providing for the public offering (the &#147;<B>Public Offering</B>&#148;) by the several Underwriters, including the Representatives (the &#147;<B>Underwriters</B>&#148;), of shares
(the &#147;<B>Shares</B>&#148;) of the common stock, par value $0.00001 per share, of the Company (the &#147;<B>Common Stock</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To induce the Underwriters to continue their efforts in connection with the Public Offering, the undersigned hereby agrees that, without the
prior written consent of Leerink Partners and Piper Sandler on behalf of the Underwriters, it will not, during the period commencing on the date hereof and ending 60 days after the date of the final prospectus (the &#147;<B>Restricted
Period</B>&#148;) relating to the Public Offering (the &#147;<B>Prospectus</B>&#148;), (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Securities Exchange Act of 1934,
as amended (the &#147;<B>Exchange Act</B>&#148;)), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock, or publicly disclose the intention to do any of the foregoing or (2)&nbsp;enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause&nbsp;(1) or (2)&nbsp;above is to be settled by
delivery of Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
transactions relating to shares of Common Stock or other securities acquired in open market transactions after the date of the Underwriting Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) transfers or dispositions of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock as a
bona fide gift, provided that any filing under Section&nbsp;16(a) of the Exchange Act required to be made during the Restricted Period in connection with any such transfer or disposition shall indicate by footnote disclosure or otherwise the nature
of the transfer or disposition; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) transfers or dispositions of shares of Common Stock or any security convertible into or
exercisable or exchangeable for Common Stock by will or other testamentary document or by intestacy; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) transfers or dispositions of
shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock that occurs by operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the exercise of options to purchase shares of Common Stock granted pursuant to Nasdaq Listing Rule 5635(c)(4) or under a stock incentive
plan or employee stock purchase plan of the Company existing as of the date hereof and described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and any related transfer of Common Stock to the Company (1)&nbsp;deemed to
occur upon the cashless exercise of such options or (2)&nbsp;for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options or as a result of the vesting
of any restricted stock units, <I>provided </I>that any shares of Common Stock issued pursuant to such exercise shall be subject to the restrictions set forth herein and any filing under Section&nbsp;16(a) of the Exchange Act required to be made
during the Restricted Period in connection with any such transfer or disposition shall indicate by footnote disclosure or otherwise the nature of the transfer or disposition; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) transfers, sales or other dispositions for the purpose of satisfying tax withholding obligations upon the vesting of equity inducement
awards granted pursuant to Nasdaq Listing Rule 5635(c)(4) or equity incentive awards granted under a stock incentive plan or employee stock purchase plan of the Company existing as of the date hereof and described in the Registration Statement, the
Time of Sale Prospectus and the Prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) transfers or distributions not involving a disposition for value of shares of Common Stock
or any security convertible into or exercisable or exchangeable for Common Stock to limited or general partners, stockholders or members of the undersigned or to a trust, partnership or other entity holding such shares of Common Stock or any
security convertible into or exercisable or exchangeable for Common Stock on behalf of or for the benefit of such limited or general partners, stockholders or members of the undersigned, or if the undersigned is a corporation, to a wholly-owned
subsidiary of the undersigned; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable for
Common Stock made by the undersigned to (1)&nbsp;any trust, corporation, partnership, limited liability company or other legal entity who, directly or indirectly, controls, is controlled by, or is under common control with the undersigned,
(2)&nbsp;any trust or other legal entity for which the undersigned or the undersigned&#146;s spouse serves as trustee or investment advisor, or (3)&nbsp;any member of the immediate family of the undersigned or any trust or other legal entity for the
direct or indirect benefit of the undersigned or any member of the immediate family of the undersigned; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) transfers of shares of Common Stock or any security convertible into or exercisable or
exchangeable for Common Stock pursuant to a sale of, or an offer to purchase, 100% of the outstanding shares of Common Stock, whether pursuant to a merger, tender offer or otherwise, to a third party or group of third parties, <I>provided</I> that
in the event that such merger, tender offer or other transaction is not completed, the Common Stock and any security convertible into or exercisable or exchangeable for Common Stock shall remain subject to the restrictions set forth herein; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) the establishment of a written trading plan that satisfies the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under
the Exchange Act (a &#147;<B><FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan</B>&#148;) for the transfer of shares of Common Stock, <I>provided</I> that (1)&nbsp;such plan does not provide for the transfer of Common Stock during the Restricted
Period and (2)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such plan, such announcement or
filing shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) the sale of Common Stock by the undersigned pursuant to a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan adopted prior to the date
hereof under which shares of Common Stock may be sold during the Restricted Period, which trading plan shall not be amended during the Restricted Period but may be terminated during the Restricted Period; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) any forfeiture, sale or other transfer to the Company of shares of Common Stock or any security convertible into or exercisable or
exchangeable for Common Stock in connection with the termination of the undersigned&#146;s employment with or services to the Company, provided that no public announcement reporting a reduction in the beneficial ownership shall be voluntarily made,
and any required announcement, including any announcement under the Exchange Act shall clearly indicate the reason for such reduction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided,</I>
<I>however, </I>that in the case of (1)&nbsp;any transfer or distribution pursuant to clause&nbsp;(b), (c), (d), (g) or (h), each donee, distributee or transferee shall sign and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter
substantially in the form of this letter, (2)&nbsp;any transaction, transfer, exercise or distribution pursuant to clause&nbsp;(a), (c), (d), (f), (g), or (h), no filing under Section&nbsp;16(a) of the Exchange Act, reporting a reduction in
beneficial ownership of shares of Common Stock, shall be required or shall be voluntarily made during the Restricted Period (other than a filing on Form 5 made after the expiration of the Restricted Period or, in the case of clause (f)&nbsp;a
required filing on Form 144 and Form 4 that clearly indicates the reason for such reduction), and (3)&nbsp;any disposition or sale pursuant to clause (k), if the undersigned is required to file a report under the Exchange Act, reporting a reduction
in the undersigned&#146;s beneficial ownership of shares of Common Stock as a result of sales made under the undersigned&#146;s <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan, the undersigned shall include a statement in such report to the
effect that such sales are being made pursuant to the undersigned&#146;s <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent
and registrar against the transfer of the undersigned&#146;s shares of Common Stock except in compliance with the foregoing restrictions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Company and the Underwriters are relying upon this
agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs, legal representatives, successors and assigns. This
agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so
delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Shares and the undersigned has
consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Underwriters may provide certain Regulation Best Interest and Form CRS
disclosures or other related documentation to you in connection with the Public Offering, the Underwriters are not making a recommendation to&nbsp;you to enter into this agreement, and nothing set forth in such disclosures or documentation is
intended to suggest that any Underwriter is making such a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement (and for the avoidance of doubt, the Restricted
Period described herein) and related restrictions shall automatically terminate upon the earliest to occur, if any, of (i)&nbsp;the Representatives, on the one hand, or the Company, on the other hand, advising the other in writing prior to the
execution of the Underwriting Agreement that they have or it has determined not to proceed with the Public Offering, (ii)&nbsp;the termination of the Underwriting Agreement before the sale of any Shares to the Underwriters, (iii)&nbsp;the
registration statement filed with the SEC with respect to the Public Offering is withdrawn or (iv)&nbsp;May&nbsp;31, 2025, in the event the closing of the Public Offering shall not have occurred on or before such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only
be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement and any claim, controversy or dispute arising under or related thereto shall be governed by and construed in accordance with
the internal laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Print Name)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Signature)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Address)</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d908870dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g908870g0320102926191.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;20, 2025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 617 526 6000 (t) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 617 526 5000
(f) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">wilmerhale.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Akebia Therapeutics, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">245 First Street, Suite 1400 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02142 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prospectus Supplement to Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you in connection with (i)&nbsp;the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-281903)</FONT> (the &#147;Registration Statement&#148;) filed by Akebia Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;), with the Securities and Exchange Commission (the
&#147;Commission&#148;) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), for the registration of, among other things, shares of the Company&#146;s common stock, $0.00001 par value per share (the &#147;Common
Stock&#148;), which may be issued from time to time on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act at an initial aggregate offering price not to exceed $250,000,000, as set forth in the Registration Statement and
the prospectus contained therein relating thereto (the &#147;Base Prospectus&#148;) and (ii)&nbsp;the prospectus supplement dated March&nbsp;19, 2025 (the &#147;Prospectus Supplement&#148; and, together with the Base Prospectus, the
&#147;Prospectus&#148;), relating to the issuance and sale pursuant to the Registration Statement of up to 28,750,000 shares of Common Stock, including up to 3,750,000 shares of Common Stock issuable upon exercise of an option to purchase additional
shares granted by the Company (collectively, the &#147;Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shares are to be issued and sold by the Company pursuant to an
underwriting agreement, dated March&nbsp;19, 2025 (the &#147;Underwriting Agreement&#148;), by and among the Company and Leerink Partners LLC and Piper Sandler&nbsp;&amp; Co., as representatives of the several underwriters named in the Underwriting
Agreement, a copy of which is filed as Exhibit 1.1 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed on the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are acting as counsel for the Company in connection with the issue and sale by the Company of the Shares. We have examined and relied upon
copies of the Registration Statement and the Prospectus, each as filed with the Commission. We have also examined and relied upon the Underwriting Agreement, records of meetings and actions of stockholders and of the Board of Directors of the
Company (and committees thereof), as provided to us by the Company, and the Ninth Amended and Restated Certificate of Incorporation of the Company and the Second Amended and Restated Bylaws of the Company, each as amended as of the date hereof, and
such other documents as we have deemed necessary for purposes of rendering the opinion hereinafter set forth. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g908870dsp50.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g908870g0320102926191.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Akebia Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;20, 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted
to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are
issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, the Shares will be validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.
This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might
affect any matters or opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion with the Commission in accordance with
the requirements of Item&nbsp;601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act as an exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed by the Company on the date
hereof in connection with the issuance and sale of the Shares and to the use of our name therein and in the Prospectus under the caption &#147;Legal Matters.&#148; In giving such consent, we do not hereby admit that we are in the category of persons
whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>/s/ Wilmer Cutler Pickering Hale and Dorr LLP</U> <U>&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">WILMER CUTLER PICKERING HALE AND DORR LLP</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d908870dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Akebia Therapeutics Announces Pricing of Public Offering of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass., March&nbsp;19, 2025 (GLOBE NEWSWIRE) &#151; Akebia Therapeutics<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Inc.
(&#147;Akebia&#148;) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering (the &#147;Offering&#148;) of 25,000,000
shares of its common stock at a public offering price of $2.00 per share. All shares are being offered by Akebia. The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expenses, are
expected to be $50.0&nbsp;million. In addition, Akebia has granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to 3,750,000 additional shares of its common stock at the public offering price, less
underwriting discounts and commissions. The Offering is expected to close on March&nbsp;21, 2025, subject to the satisfaction of customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners and Piper Sandler&nbsp;&amp; Co. are acting as joint bookrunning managers for the Offering. BTIG, LLC is acting as lead manager and H.C.
Wainwright&nbsp;&amp; Co. is acting as <FONT STYLE="white-space:nowrap">co-manager</FONT> for the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares are being offered by Akebia
pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (&#147;SEC&#148;) on September&nbsp;3, 2024 and declared effective by the SEC on September&nbsp;12, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus
supplement relating to and describing the terms of the Offering has been filed with the SEC and may be obtained for free by visiting the SEC&#146;s website at www.sec.gov. A final prospectus supplement relating to the Offering will be filed with the
SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(800)-808-7525,</FONT></FONT> ext. 6105, or by email at syndicate@leerink.com; or Piper Sandler&nbsp;&amp; Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, or by telephone at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(800)-747-3924,</FONT></FONT> or by email at prospectus@psc.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Akebia Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Akebia Therapeutics, Inc. is a
fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that involve substantial risks and uncertainties. The terms &#147;anticipate,&#148; &#147;believe,&#148; &#147;build,&#148;
&#147;can,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;should,&#148; &#147;designed,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;expect,&#148; &#147;forecast,&#148; &#147;future,&#148; &#147;goal,&#148;
&#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;strategy,&#148; &#147;seek,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would,&#148; derivatives
of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements regarding the
Offering, including the satisfaction of customary closing conditions relating to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Offering and the expected closing of the Offering. Actual results may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties related to market conditions that may affect the timing, terms and conditions of the Offering and the satisfaction of closing conditions related to the Offering. There can be no
assurance that Akebia will be able to complete the Offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements. Additional risks and uncertainties relating to the Offering, Akebia and its
business include those identified under the heading &#147;Risk Factors&#148; in Akebia&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2024, Akebia&#146;s preliminary prospectus
supplement filed with the SEC on March&nbsp;19, 2025 and other filings that Akebia may make with the SEC in the future. The forward-looking statements contained in this press release (except as otherwise noted) speak only as of the date hereof, and,
except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Akebia Therapeutics Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mercedes Carrasco </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mcarrasco@akebia.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>akba-20250319.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 3/21/2025 12:46:15 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:akba="http://akebia.com/20250319"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://akebia.com/20250319"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akba-20250319_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akba-20250319_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>akba-20250319_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 3/21/2025 12:46:15 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>akba-20250319_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 3/21/2025 12:46:15 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="akba-20250319.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g908870dsp50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g908870dsp50.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MI'=:]<LNG6-HDY,,/VVXO98KE+ VET ;>K:V/ =]I-UXB\2ZEJ6D>)M8\/\
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M R_$NV67P_J@O-<\!R2101^(]#LEMS->6XFN+19;618;RU%]:/>6UO%>0/,
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M;V"V#PQ>=X4L6U""\2X>SF@N()H[AH7,B '<>#O%NB^.O#6D^*_#TT\VD:Q
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MMS6%S96]I/ FI3PR231L%4V\@V\CTGQ9\,],\8?##4_A3J>M^(;?1=8\,_\
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MC)=:5J_Q(T:[T.W@E\)ZUH]EX7N6NIC;^)[*?3O UQKZS8@!L=5TNY\8VY,
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MX>ZG7[7>W%_-OGD^9_\ 2+J4C/0$ <"@#H: "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
A * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g908870g0320102926191.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g908870g0320102926191.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  4 (H# 2(  A$! Q$!_\0
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IL$,LAD=0\1^8]3S'Q5RW\(Z)!;10FR27RT">9+R[8&,L>Y/>BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 19, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001517022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 19,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AKEBIA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8756903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245 First Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">871-2098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AKBA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  >&=%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    (  >&=%JZ 8V0[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  'AG1:EXJ[',     3 @
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
M!X9T6F60>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P
M$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>L
MWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH
M>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G
M(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6
M&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O
M>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+
MX3]>?P%02P$"% ,4    "  'AG1:1L=-2)4   #-    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  >&=%JZ 8V0[P
M "L"   1              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    (  >&=%J97)PC$ 8  )PG   3              "  >$!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ !X9T6N?]AK97!   E!   !@
M             ("!(@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    (  >&=%J?H!OPL0(  .(,   -              "  :\,  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ !X9T6I>*NQS     $P(   L
M     ( !BP\  %]R96QS+RYR96QS4$L! A0#%     @ !X9T6APX9>H_ 0
M/ (   \              ( !=!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   (  >&=%HD'INBK0   /@!   :              "  > 1  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  >&=%IED'F2&0$  ,\#
M   3              "  <42  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(   \4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d908870d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>akba-20250319.xsd</File>
    <File>akba-20250319_lab.xml</File>
    <File>akba-20250319_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d908870d8k.htm">d908870d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d908870d8k.htm": {
   "nsprefix": "akba",
   "nsuri": "http://akebia.com/20250319",
   "dts": {
    "schema": {
     "local": [
      "akba-20250319.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "akba-20250319_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "akba-20250319_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d908870d8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-03-19_to_2025-03-19",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d908870d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-03-19_to_2025-03-19",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d908870d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://akebia.com//20250319/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193125-25-059327-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-059327-xbrl.zip
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M.M%OV'> +SP#?,LXW,^S$:C3:&[KJHYNV^N&4^/,,TY#NNRE6 8V9NOE@]=
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M3ST;N?6$\'L4I!N!CF4=[ '.IW%8KQ_/^M?'A6(SKXRFD+QRD&>[Y)G!+*^
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M4LQ$JZK%;.-1!4)TD#%E?@5J:[(-!UE>!3.0CO"1*&OL,9I,$CQL^-(];??
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MJUD91L2L:+95SVU8>9SF)3*/RX";C&CCEG1L0+P_N1H@T[KN!G<W,BH+!K#
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M$>H=:VCV22SN^ 5:K_3G"1X!F@%*NGU.\&_<S]_HSW2UV'DQX>)!*A2IX>_
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M!_,815(!!:S>$0^#M]RHA1L..%[@4]2%;0G96S5K4_]KY(1JC.C5"4_PL7Q
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MY'O$(\V3->OZZ=G>;H-+P/)/Z](B@+2^ND8*1[C"<<2O\20AVF\P5,0__J[
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M:N^\RBA1[-?CE48UWE=0,Q7'F\'1E8N]VIUO!L*FI3=L>7<4E(NRBLFCE@D
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M9EV[,JXDF^"PS7B<1D4["D8&>[0@Y2C"0-\@ [:N/D+ZHK7 ;0Q]XT BA%8
MIZ*,F6WX8%KC%+U=ZR'A?-,Q2(8'A/^5L>'4WP/[P4HS?PHT@<&C(@BHQG-_
M!ZSS1<F8=&S+NIZSQCC)3"U7GL:$YLC<8B6+2,>6L$#WH1K^Y568[BTBH_0Y
M1MS!I9^T'1RAN+8BB+X\JTN>1@4;!M6(=%7.).Q:@/CHAC>H!&=QAJ$Q\0(7
M9K)5'!4XS2VPM<<8*T,J3\0I;O%$1@!_EM[X#KV&TBW"$EX-JMD./LBH:/@L
M@9=%/# ;-M6F;P=E@@UXJ96S'[B%\Y 7/1R P1)[/GY3ZUU5]:SB %USP_ S
MJG & [ IS1.H:+[ 6+YKSKT,%G)K;#>4Q,M'<"XL$=%WHS&-6)'"X'H42,[1
MQ+0K&PY6,Z>YO#[-T,:CD67^3E?JT<"JT,!J4'I$-'-GK@DO6^I<OG[=_=MA
M^V2'2:+J@Q2THM7E^Z(80IU<)'+/\>2L8/<N/!U6&=N:QLBDYFRM;.=D$SY?
M9X:=6"8I<PR3V%O54US$<L;KJI5( CA%*CI."'<9KK^P;H_=&TKYUJZGX.L0
M2''/[EN7E3;J$@BR?6MNLK703 WKRMOK1$-OQ */F 48HIY(^1IN+DB(!=O?
MYB]= M'J9BPV;:9886]O',*65&G5H)-Q&">#/&!=HBN/AB_@NOZ9%Y^#PX1G
M$;?D,ITU:L?E-@J#LTKF1_H@*.68.=%"Z2[[YPDY7@V56E%MY!1>XBD;BE81
M6U*LW9&AKMBI(U%+)J2IRQ;.:4(P,\?1TB1TYT3(W)Q)$7NNA(:B$^EEM8(6
M;:@-MB7+^<W&B1Y_CQ/=YFW7MWF%O7VE.ST<J$L=K+[3Q.BM++"#D40>%OO-
MJQWP,E![ZUURH_WU/1<X089XOM:E1]ME!!=Y[3OO0]S=IQ]\VA#;9D%+G2U;
M76/'+=J9VA@IIU_!<G*#U&F-.GZ&P%EH<C3(C"8\X=1[5)X725Y8MM.&FN@?
M%=/L,.="(Q$1,D+.*+2Z2QD=4BQD,U'=T2.;?B5HNRFY581<8=S"GL27^7C@
M6S1=OC^HK07YQ:%%5S2"WSANGI_-? @[NG]K\3&9"H<NP-6Q'S09X$.<+I4?
M@@\NINN,2T-Q'?#M<I*IF,Z+L6'A*U9;&)AG7LWS!\\CR_S#%1&F1NIS2<#)
M74?J2))0.0WQ) E&'MZ88CY:K IF#&5T,U,P9MZJ[LK#)]Y'F\%)/2I15&0V
M@,H(E28_.A%C5)P#CSR<<^V1%]=AAQMVRV]*&I./S<Z8MM,#*#*57V9G1<3@
MWQA0X \KJ!&7!*6P!6V<=6]E471=VZMZ'A>8T&>+^"*!E9&6)[!YPN*3 AWR
M7B9Y7,J8#V[38?Y)"I<?(0?&_ZYM1RLX+\/ENK(U*TEM*6*KE*:W=9H'JICB
M/=8HDIZW$^$QA(X(AXC")._/B[,H$T3-4$S=OF: IO6PCR,EG^S9?C)=P,2E
M]O<M7PEO834+F:,0<DY CJ8Y59P$5T0-CKQ^5/^(*2O'HC54=;O&[+M,2EZ"
M,$3,X[W+T*KS4-?+Y5ZSUQK5'UTX2I(,08NO65S=5T!M<()\IY\ JET*+;-
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M%WTX6)(JO)VW]XNBK\#:/4?U'IJ<-WME'"W!HR8\89O=G"8%:!>=X^R&Y5;
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M=K8LK*F+0T_3B;\SC=(2;%W"Z(]%GT]TY*OW2QD<$RGYA_>;Z@YY9EG/M[I
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M.U)],3N<W*FQ)3!O XZ)GX92X,##>C,6&E:E9\&6%*B"^OQ)1@CQ?4/27WR
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MGUVW_V1GYZWKWG7_M'1[T1UV2FPP_+/7.2UYTA=;4R$GT^CX*E S[I4:K%C
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MGSM]>"F[:,*-FU=MUK[N]ZT1%NC.WLH^/;.H[] ?.V'1_(G4_P!02P,$%
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M,#@X-S!D.&LN:'1M4$L! A0#%     @ !X9T6J8/&O#D@0  E*P" !
M         ( !'"8  &0Y,#@X-S!D97@Q,2YH=&U02P$"% ,4    "  'AG1:
M3!]G$A8+   I)0  $               @ $NJ   9#DP.#@W,&1E>#4Q+FAT
M;5!+ 0(4 Q0    (  >&=%IZ("=^?0H  %,>   1              "  7*S
I  !D.3 X.#<P9&5X.3DQ+FAT;5!+!08     !P ' +P!   >O@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>d908870d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="akba-20250319.xsd" xlink:type="simple"/>
    <context id="duration_2025-03-19_to_2025-03-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <startDate>2025-03-19</startDate>
            <endDate>2025-03-19</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2025-03-19_to_2025-03-19"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-313">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-03-19_to_2025-03-19"
      id="Hidden_dei_EntityCentralIndexKey">0001517022</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-324">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-325">2025-03-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-326">AKEBIA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-327">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-328">001-36352</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-329">20-8756903</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-330">245 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-331">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-332">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-333">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-334">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-335">871-2098</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-336">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-337">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-338">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-339">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-340">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-341">AKBA</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-03-19_to_2025-03-19" id="ixv-342">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
